Pfizer Inc (PFE) 35.29 $PFE Pharma ETFs Soaring on Solid

Pfizer Inc (PFE) 35.29 $PFE

Pharma ETFs Soaring on Solid Q2 Earnings
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 11:22AM CDT
Pharma ETFs are in focus in the days ahead on impressive Q2 results.
IHE: 156.52 (+0.77), BIIB: 321.34 (-8.77), JNJ: 123.90 (-0.95), PPH: 61.96 (+0.06), PJP: 68.56 (+0.47), MRK: 57.65 (-0.68), PFE: 35.29 (-1.10), XPH: 46.68 (+0.54), LLY: 82.72 (-0.60), BMY: 74.80 (-0.25)

Business Highlights
By The Associated Press - AP - Tue Aug 02, 4:19PM CDT
___
F: 12.13 (+0.19), PFE: 35.29 (-1.10), GM: 30.24 (+0.31), CVS: 97.43 (-0.63), TM: 110.07 (+0.10), PG: 85.97 (-0.79), AET: 116.86 (+1.15)

Royal Caribbean and General Motors fall; CVS advances
AP - Tue Aug 02, 3:51PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
MNK: 79.66 (+2.75), DISCK: 25.91 (+0.50), F: 12.13 (+0.19), DAL: 36.48 (+0.09), PFE: 35.29 (-1.10), STX: 30.73 (+0.08), DISCB: 25.82 (-0.03), DISCA: 26.83 (+0.41), CVS: 97.43 (-0.63), GM: 30.24 (+0.31)

Pfizer Set to Possibly Rebound After Yesterday's Selloff of 2.28%
Comtex SmarTrend(R) - Tue Aug 02, 11:52AM CDT
Pfizer (NYSEFE) traded in a range yesterday that spanned from a low of $36.13 to a high of $36.82. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low of $36.50 on volume of 17.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
PFE: 35.29 (-1.10)

What's in Store for Merck KGaA (MKGAF) in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 9:06AM CDT
Merck KGaA (MKGAF) is scheduled to report second-quarter 2016 earnings results on Aug 4.
IPXL: 31.62 (+0.65), IRWD: 14.24 (+0.41), PFE: 35.29 (-1.10)

Q2 Earnings Reports Come in Mixed, Futures Down Slightly
Mark Vickery - Zacks Investment Research - Tue Aug 02, 8:58AM CDT
Q2 earnings season may have passed the midway point last week, but plenty of important companies are reporting earnings this morning: PFE, PG, MNT, CVS, SODA and RCL.
RCL: 68.77 (+1.42), PFE: 35.29 (-1.10), CVS: 97.43 (-0.63), PG: 85.97 (-0.79), SODA: 27.48 (-0.77)

Global Pain Management Therapeutics Market - Patent Expiries of Blockbuster Drugs to Intensify Challenges for Branded Drugs, States TMR; Industry Analysis, Size, Share, Growth, Trends, Forecast up to 2023
PR Newswire Europe - Tue Aug 02, 8:31AM CDT
ALBANY, New York, August 2, 2016 /PRNewswire/ --
PFE: 35.29 (-1.10), MRK: 57.65 (-0.68)

Pfizer (PFE) Tops on Q2 Earnings, Revenues, Maintains View
Arpita Dutt - Zacks Investment Research - Tue Aug 02, 8:08AM CDT
Pfizer (PFE) surpassed earnings and revenue estimates again in the second quarter.
JNJ: 123.90 (-0.95), PFE: 35.29 (-1.10), LLY: 82.72 (-0.60), BMY: 74.80 (-0.25)

Pfizer (PFE) Beats on Q2 Earnings and Revenues
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:14AM CDT
Pfizer's (PFE) second quarter results surpassed expectations with the company beating on the top- and bottom-line.
PFE: 35.29 (-1.10)

PFIZER REPORTS SECOND-QUARTER 2016 RESULTS
BusinessWire - Tue Aug 02, 5:45AM CDT
--Second-Quarter 2016 Revenues for Pfizer Standalone (Excluding Legacy Hospira) of $12.0 Billion, Reflecting 4% Operational Growth
PFE: 35.29 (-1.10)

Blue Chip Stock Earnings Preview: PFE, PG, HUM
Eric Dutram - Zacks Investment Research - Mon Aug 01, 6:25PM CDT
Three blue chip companies are giving their quarterly reports this week, which should you be paying close attention to?
PFE: 35.29 (-1.10), PG: 85.97 (-0.79), HUM: 173.48 (+3.91)

Business events scheduled for Tuesday
By The Associated Press - AP - Mon Aug 01, 1:24PM CDT
Major business and economic events scheduled for Tuesday:
PFE: 35.29 (-1.10), PG: 85.97 (-0.79), AET: 116.86 (+1.15)

Pfizer Aims to Become Industry Leader in Gene Therapy with Acquisition of Bamboo Therapeutics, Inc.
BusinessWire - Mon Aug 01, 9:00AM CDT
Pfizer Inc. (NYSEFE) today announced that it has acquired Bamboo Therapeutics, Inc., a privately held biotechnology company based in Chapel Hill, N.C., focused on developing gene therapies for the potential treatment of patients with certain rare diseases related to neuromuscular conditions and those affecting the central nervous system. This acquisition significantly expands Pfizer's expertise in gene therapy by providing Pfizer with a clinical and several pre-clinical assets that complement the company's rare disease portfolio, an advanced recombinant Adeno-Associated Virus (rAAV) vector design and production technology, and a fully functional Phase I/II gene therapy manufacturing facility that Bamboo acquired from the University of North Carolina earlier this year.
PFE: 35.29 (-1.10)

What Awaits MNK & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:00AM CDT
Let's see what's in store for some medical companies that are expected to declare quarterly numbers on Aug 2.
MNK: 79.66 (+2.75), BIIB: 321.34 (-8.77), ABT: 44.95 (-0.12), JNJ: 123.90 (-0.95), GILD: 80.09 (+0.52), MRK: 57.65 (-0.68), PFE: 35.29 (-1.10), SGNT: 21.71 (-0.03), ABBV: 66.57 (-0.21), PRTA: 58.27 (+2.66), NVS: 82.40 (-0.56)

Watch for Shares of Pfizer (PFE) to Approach Resistance at $37.13
Comtex SmarTrend(R) - Mon Aug 01, 8:34AM CDT
Shares of Pfizer (NYSEFE) opened today above their pivot of $36.83 and have already reached the first level of resistance at $37.01. Should the shares continue to rise, the resistance pivots of $37.13 and $37.43 will be of interest.
PFE: 35.29 (-1.10)

First Majestic Silver trade offers a 7% return in 172 days, or find similar option trades on Newell Brands Incorporated, Pfizer Inc., Wells Fargo & Co., and Starbucks
PR Newswire - Mon Aug 01, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AG, NWL, PFE, SBUX, and WFC.
SBUX: 55.94 (-0.79), AG: 18.20 (+0.16), NWL: 53.51 (-0.31), PFE: 35.29 (-1.10), WFC: 47.57 (-0.13)